249 related articles for article (PubMed ID: 27092498)
21. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
23. [Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma].
Zheng Q; Tang Z; Wu Z; Shi D; Song H
Zhonghua Wai Ke Za Zhi; 1998 Aug; 36(8):474-6. PubMed ID: 11825444
[TBL] [Abstract][Full Text] [Related]
24. Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway.
Chen K; Zhang S; Ji Y; Li J; An P; Ren H; Liang R; Yang J; Li Z
PLoS One; 2013; 8(9):e72927. PubMed ID: 24039823
[TBL] [Abstract][Full Text] [Related]
25. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
26. Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity.
Yeh CB; Hsieh MJ; Hsieh YH; Chien MH; Chiou HL; Yang SF
PLoS One; 2012; 7(2):e31055. PubMed ID: 22363545
[TBL] [Abstract][Full Text] [Related]
27. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
Morita Y; Hayashi Y; Kanamaru T; Itoh T; Suzuki S; Yamamoto M; Kuroda Y; Itoh H
Jpn J Cancer Res; 1999 Jul; 90(7):747-52. PubMed ID: 10470287
[TBL] [Abstract][Full Text] [Related]
29. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
30. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
31. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
32. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
33. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
34. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
36. Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways.
Ma CY; Ji WT; Chueh FS; Yang JS; Chen PY; Yu CC; Chung JG
J Agric Food Chem; 2011 Aug; 59(16):9032-8. PubMed ID: 21770460
[TBL] [Abstract][Full Text] [Related]
37. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
38. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway.
Chou RH; Hsieh SC; Yu YL; Huang MH; Huang YC; Hsieh YH
PLoS One; 2013; 8(8):e71983. PubMed ID: 23940799
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
[TBL] [Abstract][Full Text] [Related]
40. Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression.
Tsai JP; Hsiao PC; Yang SF; Hsieh SC; Bau DT; Ling CL; Pai CL; Hsieh YH
PLoS One; 2014; 9(1):e86537. PubMed ID: 24466137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
